Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007008859) METHODS OF ENHANCING THE IMMUNE RESPONSE TO AUTOANTIGENS IN MUCOSAL ASSOCIATED LYMPHATIC TISSUE
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

I claim:

1. A method of inducing tolerance to an antigen in a mammal, comprising the steps of :

a) irradiating mucosal associated lymphatic tissue (MALT) in the mammal with an effective amount of UV light, and
b) mucosally administering an effective amount of the antigen to the mammal.

2. The method of claim 1 wherein step a) is initiated before step b).

3. The method of claim 1 wherein step a) is carried out in a plurality of doses.

4. The method of claim 3 wherein at least one of the doses provides between 0.02 J/cm and 2 J/cm2 of energy.

5. The method of claim 1 wherein the antigen is a CNS antigen.

6. The method of claim 1 wherein the antigen is MBP.

7. The method of claim 1 wherein the antigen is MOG.

8. The method of claim 1 wherein the antigen is ╬▓AP.

9. The method of claim 1 wherein the antigen is E-selectin.

10. The method of claim 1 wherein the antigen is type II collagen.

11. The method of claim 1 wherein the antigen is insulin.

12. The method of claim 1 wherein the irradiation of the MALT is effective to produce IL-IO.

13. The method of claim 1 wherein the antigen is selected from the group consisting of a neuritogenic peptide of PNS myelin component P2, a neuritogenic peptide of PNS myelin component PO, and a ganglioside.

14. The method of claim 1 wherein the antigen is a wear particle.

15. The method of claim 1 wherein the MALT is NALT.

16. The method of claim 1 wherein at least a portion of adenoid tissue is irradiated.

17. The method of claim 1 wherein the MALT is GALT.

18. The method of claim 17 wherein the irradiation of the GALT is accomplished by a probe.

19. The method of claim 17 wherein the irradiation is provided by a pill.

20. The method of claim 1 wherein the MALT is BALT.

21. The method of claim 1 wherein the UV irradiation comprises an effective amount of UVB irradiation.

22. The method of claim 1 wherein the UV irradiation is narrowband UVB irradiation.

23. The method of claim 1 wherein the UV irradiation comprises an effective amount of UVA irradiation.

24. The method of claim 23 wherein an effective amount of a photoactivatable agent is co-administered with the UVA irradiation.

25. A method of inducing tolerance to an antigen in a mammal, comprising the steps of :

a) irradiating a nasal mucosa in the mammal with an effective amount of UV light, and
b) nasally administering an effective amount of the antigen to the mammal.

26. The method of claim 25 wherein step a) is initiated before step b).

27. The method of claim 25 wherein step a) is carried out in a plurality of doses.

28. The method of claim 27 wherein at least one of the doses provides between 0.02 J/cm2 and 2 J/cm2 of energy.

29. The method of claim 25 wherein the antigen is a CNS antigen.

30. The method of claim 25 wherein the antigen is selected from the group consisting of is MBP, MOG, BAP, e-selectin and type II collagen.

31. The method of claim 25 wherein the antigen is insulin.

32. The method of claim 25 wherein the irradiation of the nasal mucosa is effective to produce IL-10.

33. The method of claim 25 wherein the antigen is selected from the group consisting of a neuritogenic peptide of PNS myelin component P2, a neurito genie peptide of PNS myelin component PO, and a ganglioside.

34. The method of claim 25 wherein the UV light comprises an effective amount of UVB light.

35. A kit for inducing tolerance in a mammal, comprising:

a) a formulation comprising an antigen in an amount effective to produce
tolerance via nasal installation, and
b) an intranasal UVB probe.

36. A method of inducing tolerance to an antigen in a mammal, comprising the steps of :

a) mucosally administering a formulation comprising an effective amount of the antigen and TGF-B to the mammal.

37. A method of inducing tolerance to an antigen in a mammal, comprising the steps of :

a) mucosally administering a formulation comprising an effective amount of the antigen and PGE2 to the mammal.

38. A method of inducing tolerance to an antigen in a mammal, comprising the steps of :

a) mucosally administering a formulation comprising an effective amount of the antigen and immature dendritic cells to the mammal.

39. A method of inducing tolerance to an antigen in a mammal, comprising the steps of :

a) irradiating nasal lymphatic tissue in the patient with an effective amount of UV light to produce e-selectin in an amount sufficient to tolerize the mammal to e- selectin.

40. A method of inducing tolerance to an antigen in a mammal, comprising the steps of :

b) nasally administering a formulation comprising an effective amount of the antigen and alum to the mammal.